UK's MHRA suspends Valneva's chikungunya vaccine for elderly

The UK's MHRA has temporarily restricted the use of Valneva's chikungunya vaccine, IXCHIQ, for individuals aged 65 and above, citing 23 cases of serious adverse reactions, including two fatalities, in the 62-89 age group following vaccinations in La Reunion. This decision follows similar suspensions by the EMA, FDA, and CDC in May, and a prior action by the French government in April, raising concerns about the vaccine's safety profile for elderly recipients despite its approval for adults 18 and older.

Analysis

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has temporarily restricted Valneva's chikungunya vaccine, IXCHIQ, for individuals aged 65 and above, citing 23 global cases of serious adverse reactions, including two fatalities, in vaccine recipients aged 62 to 89. This precautionary measure, occurring before IXCHIQ's UK market launch despite its February approval for adults 18 and older, follows similar suspensions of the vaccine for the elderly by the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and Centers for Disease Control and Prevention (CDC) in May, and an earlier action by the French government in April. The consistent pattern of regulatory intervention across multiple major jurisdictions underscores significant safety concerns for this demographic, potentially limiting IXCHIQ's market penetration and impacting Valneva's commercial outlook for the product, particularly within the elderly population which represents a key target group for such vaccines.

Key Decisions for Investors

• Investors should anticipate a negative impact on Valneva's (VLS.PA, VALN) projected revenues for IXCHIQ due to the growing list of regulatory restrictions in key markets for the 65+ age group.
• Monitor upcoming announcements from Valneva and regulatory agencies regarding further investigations into the adverse events and any potential label changes, as these will be critical determinants of the vaccine's future.
• Exercise caution regarding Valneva's near-term stock performance, as the repeated safety-driven suspensions by prominent regulatory bodies like MHRA, EMA, and FDA increase uncertainty and risk surrounding IXCHIQ's commercial success.